Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Antitumor treatment may increase risk of severe events in COVID-19 patients

Publish date:: May 1, 2020

Key clinical point: Cancer patients who received antitumor treatment within 14 days of COVID-19 diagnosis had an increased risk of severe events, defined as ICU admission, mechanical ventilation, or death.

Major finding: In a multivariable analysis, receiving antitumor treatment within 14 days was significantly associated with severe events (hazard ratio, 4.079; P = .037).

Study details: A retrospective study of 28 patients with cancer and COVID-19.

Disclosures: Dr. Zhang and colleagues reported no conflicts of interest. The research was funded by the National Natural Science Foundation of China and Huazhong University of Science and Technology COVID-19 Rapid Response Call China.

Citation:

Zhang L et al. Ann Oncol. 2020 Mar 26. doi: 10.1016/j.annonc.2020.03.296.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in COVID-19 Updates

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Obesity, hypoxia predict severity in children with COVID-19,

Whales, seals, and dolphins: Will SARS-CoV-2–contaminated wastewater prove a killer?,

COVID-19 in pregnancy raises risk of preterm birth and severe disease,

New case suggestive of in utero SARS-CoV-2 transmission,